606 related articles for article (PubMed ID: 34918245)
1. Developments in Vaccine Adjuvants.
Firdaus FZ; Skwarczynski M; Toth I
Methods Mol Biol; 2022; 2412():145-178. PubMed ID: 34918245
[TBL] [Abstract][Full Text] [Related]
2. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
Del Giudice G; Rappuoli R; Didierlaurent AM
Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
[TBL] [Abstract][Full Text] [Related]
3. Research progress in the development of natural-product-based mucosal vaccine adjuvants.
Gao Y; Guo Y
Front Immunol; 2023; 14():1152855. PubMed ID: 37090704
[TBL] [Abstract][Full Text] [Related]
4. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity.
Shi S; Zhu H; Xia X; Liang Z; Ma X; Sun B
Vaccine; 2019 May; 37(24):3167-3178. PubMed ID: 31047671
[TBL] [Abstract][Full Text] [Related]
5. Modes of Action for Mucosal Vaccine Adjuvants.
Aoshi T
Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in self-adjuvanting glycoconjugate vaccines.
Manabe Y; Chang TC; Fukase K
Drug Discov Today Technol; 2020 Dec; 37():61-71. PubMed ID: 34895656
[TBL] [Abstract][Full Text] [Related]
7. Precision Vaccine Adjuvants for Older Adults: A Scoping Review.
Nanishi E; Angelidou A; Rotman C; Dowling DJ; Levy O; Ozonoff A
Clin Infect Dis; 2022 Aug; 75(Suppl 1):S72-S80. PubMed ID: 35439286
[TBL] [Abstract][Full Text] [Related]
8. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
Jin Z; Gao S; Cui X; Sun D; Zhao K
Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
[TBL] [Abstract][Full Text] [Related]
9. Potentials of saponins-based adjuvants for nasal vaccines.
Chen K; Wang N; Zhang X; Wang M; Liu Y; Shi Y
Front Immunol; 2023; 14():1153042. PubMed ID: 37020548
[TBL] [Abstract][Full Text] [Related]
10. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
11. Vaccine Adjuvants: Selection Criteria, Mechanism of Action Associated with Immune Responses and Future Directions.
Habib A; Anjum KM; Iqbal R; Jaffar G; Ashraf Z; Khalid MS; Taj MU; Zainab SW; Umair M; Zohaib M; Khalid T
Iran J Immunol; 2023 Mar; 20(1):1-15. PubMed ID: 36917475
[TBL] [Abstract][Full Text] [Related]
12. Study of Agonists of TLRs as Vaccine Adjuvants.
Mancini F; Micoli F; Rossi O
Methods Mol Biol; 2023; 2700():249-269. PubMed ID: 37603186
[TBL] [Abstract][Full Text] [Related]
13. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity.
Li Z; Zhao Y; Li Y; Chen X
Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33494477
[TBL] [Abstract][Full Text] [Related]
14. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.
Caproni E; Tritto E; Cortese M; Muzzi A; Mosca F; Monaci E; Baudner B; Seubert A; De Gregorio E
J Immunol; 2012 Apr; 188(7):3088-98. PubMed ID: 22351935
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvants to engage the cross-presentation pathway.
Lee W; Suresh M
Front Immunol; 2022; 13():940047. PubMed ID: 35979365
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in adjuvants for vaccines against infectious diseases.
O'Hagan DT; MacKichan ML; Singh M
Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
[TBL] [Abstract][Full Text] [Related]
17. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives.
Zeng Y; Zou F; Xia N; Li S
Expert Rev Vaccines; 2023; 22(1):681-695. PubMed ID: 37496496
[TBL] [Abstract][Full Text] [Related]
18. Adjuvants for swine vaccines: Mechanisms of actions and adjuvant effects.
Charerntantanakul W
Vaccine; 2020 Oct; 38(43):6659-6681. PubMed ID: 32888738
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor agonists as cancer vaccine adjuvants.
Jeon D; Hill E; McNeel DG
Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
[TBL] [Abstract][Full Text] [Related]
20. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
